The association of trastuzumab, pertuzumab and docetaxel is considered the standard first-line treatment in HER2-enriched advanced BC, according to the CLEOPATRA trial; however, data on activity in BM or LM are lacking, as the enrollment of patients with CNS recurrences were not allowed [166]. This evidence concerns the gene ERBB2 and breast cancer.